Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants.
作者信息
Tartof Sara Y, Slezak Jeff M, Puzniak Laura, Hong Vennis, Xie Fagen, Ackerson Bradley K, Valluri Srinivas R, Jodar Luis, McLaughlin John M
机构信息
Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, CA 91101, USA; Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA USA.
Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, CA 91101, USA.
出版信息
Lancet Respir Med. 2022 Jul;10(7):e61-e62. doi: 10.1016/S2213-2600(22)00170-9. Epub 2022 May 6.
Abstract
摘要
相似文献
1
Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants.BNT162b2疫苗在免疫功能低下人群中针对奥密克戎和德尔塔变异株所致严重后果的有效性和持久性
Lancet Respir Med. 2022 Jul;10(7):e61-e62. doi: 10.1016/S2213-2600(22)00170-9. Epub 2022 May 6.
2
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
3
Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents.BNT162b2疫苗对青少年中德尔塔和奥密克戎变种的有效性
Pediatrics. 2022 Sep 1;150(3). doi: 10.1542/peds.2022-057634.
4
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.加强剂对康复的 COVID-19 患者血清中和针对奥密克戎变异株的活性：BNT162b2 和科兴疫苗的效果。
EBioMedicine. 2022 May;79:103986. doi: 10.1016/j.ebiom.2022.103986. Epub 2022 Apr 8.
5
Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.新冠病毒疫苗应答和针对德尔塔和奥密克戎变异株的第三剂加强针诱导中和抗体的比较分析。
Nat Commun. 2022 May 5;13(1):2476. doi: 10.1038/s41467-022-30162-5.
6
Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.同源和异源 BNT162b2、CoronaVac 和 AZD1222 加强疫苗对 Delta 和奥密克戎 SARS-CoV-2 感染的真实世界有效性。
Emerg Microbes Infect. 2022 Dec;11(1):1343-1345. doi: 10.1080/22221751.2022.2072773.
7
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.BNT162b2疫苗加强针在疗养院居民中针对新冠病毒德尔塔和奥密克戎变异株的免疫原性：一项针对68至98岁老年人的前瞻性观察研究。
Lancet Reg Health Eur. 2022 Jun;17:100385. doi: 10.1016/j.lanepe.2022.100385. Epub 2022 Apr 21.
8
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.mRNA 疫苗为预防不同关切的 SARS-CoV-2 变异株提供了广泛保护。
Emerg Microbes Infect. 2022 Dec;11(1):1550-1553. doi: 10.1080/22221751.2022.2081616.
9
Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.在先前接种科兴疫苗的老年人中，接种ChAdOx-1或BNT162b2加强针后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的中和抗体及T细胞反应
Immun Ageing. 2022 May 24;19(1):24. doi: 10.1186/s12979-022-00279-8.
10
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
引用本文的文献
1
Impact of Preexisting Rare Diseases on COVID-19 Severity, Reinfection, and Long COVID, and the Modifying Effects of Vaccination and Antiviral Therapy: A Retrospective Study from the N3C Data Enclave.既往罕见病对新冠病毒疾病严重程度、再感染及新冠长期症状的影响，以及疫苗接种和抗病毒治疗的调节作用：一项来自国家COVID-19合作数据库（N3C数据专区）的回顾性研究
medRxiv. 2025 Jul 10:2025.07.09.25331138. doi: 10.1101/2025.07.09.25331138.
2
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.癌症导致免疫功能低下人群中 COVID-19 的疾病负担：专家意见综述
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf074.
3
Using surveillance data to evaluate the effectiveness of inactivated/mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the current ambit of SARS-CoV-2 XBB and JN.1 variant circulation.在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）XBB和JN.1变体传播的当前范围内，利用监测数据评估新型冠状病毒灭活/信使核糖核酸（COVID-19）疫苗加强针在预防重症COVID-19病例死亡结局方面的有效性。
Front Public Health. 2025 May 14;13:1497399. doi: 10.3389/fpubh.2025.1497399. eCollection 2025.
4
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period.AZD7442（替沙格韦单抗/西加韦单抗）在以色列奥密克戎亚变体时期用于预防COVID-19住院的暴露前预防效果。
Infect Dis Ther. 2025 Feb;14(2):433-445. doi: 10.1007/s40121-024-01100-3. Epub 2025 Jan 7.
5
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
6
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.在法国，免疫功能低下的患者接种了针对变异株的改良 mRNA COVID-19 疫苗后，疾病的临床和经济负担大大减轻。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2423474. doi: 10.1080/21645515.2024.2423474. Epub 2024 Nov 14.
7
No more government-imposed societal-level COVID-19 control measures but still significant self-experienced burden for severely immunocompromised individuals - A cross-sectional survey in the Netherlands.不再有政府强制实施的社会层面新冠疫情防控措施，但严重免疫功能低下个体仍有明显的自我感受负担——荷兰的一项横断面调查
Prev Med Rep. 2024 Jul 14;45:102827. doi: 10.1016/j.pmedr.2024.102827. eCollection 2024 Sep.
8
Risk Factors for Recurrent Urinary Tract Infections Among Women in a Large Integrated Health Care Organization in the United States.美国大型综合医疗机构中女性复发性尿路感染的危险因素。
J Infect Dis. 2024 Nov 15;230(5):e1101-e1111. doi: 10.1093/infdis/jiae331.
9
Effectiveness of COVID-19 mRNA vaccine in preventing infection against Omicron strain: Findings from the Hiroshima Prefecture COVID-19 version J-SPEED for PCR center.新冠病毒mRNA疫苗预防奥密克戎毒株感染的有效性：广岛县新冠病毒J-SPEED版PCR中心的研究结果
PLOS Glob Public Health. 2024 Apr 17;4(4):e0003071. doi: 10.1371/journal.pgph.0003071. eCollection 2024.
10
Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study.奥密克戎时代新冠病毒病对免疫功能低下人群的影响：基于观察性人群的INFORM研究的见解
Lancet Reg Health Eur. 2023 Oct 13;35:100747. doi: 10.1016/j.lanepe.2023.100747. eCollection 2023 Dec.
本文引用的文献
1
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.mRNA 疫苗预防卡塔尔奥密克戎 BA.1 和 BA.2 亚变种对 SARS-CoV-2 的保护持续时间。
Nat Commun. 2022 Jun 2;13(1):3082. doi: 10.1038/s41467-022-30895-3.
2
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.美国大型医疗体系中，针对奥密克戎和德尔塔变异株，BNT162b2 疫苗对住院和急诊科就诊的持久性：一项病例对照研究。
Lancet Respir Med. 2022 Jul;10(7):689-699. doi: 10.1016/S2213-2600(22)00101-1. Epub 2022 Apr 22.
3
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.第二剂 BNT162b2 疫苗对 60 岁以上成年人因 COVID-19 住院和死亡的有效性。
Nat Med. 2022 Jul;28(7):1486-1490. doi: 10.1038/s41591-022-01832-0. Epub 2022 Apr 25.
4
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.在全国范围内接种第四剂 BNT162b2 mRNA 新冠疫苗。
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
5
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.在以色列，第四剂 BNT162b2 对奥密克戎的保护作用。
N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
6
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study.第三剂BNT162b2 mRNA新冠疫苗在美国大型医疗系统中的有效性：一项回顾性队列研究。
Lancet Reg Health Am. 2022 May;9:100198. doi: 10.1016/j.lana.2022.100198. Epub 2022 Feb 14.
Zotero 插件